InflaRx N.V.
InflaRx N.V. is testing IFX-1, a monoclonal anti-human complement factor C5a antibody currently under development as treatment for inflammatory conditions and COVID-19 pneumonia.
Rankings by
National Ranking41st
in Germany Regional Ranking318th
in Western Europe Global Ranking1452nd
worldwide